NASDAQ: NKGN - NKGen Biotech, Inc.

Yield per half year: -66.77%
Sector: Healthcare

Share chart NKGen Biotech, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 1.92
Выручка 0.000426
P/S 591.6
P/BV -6.62
ISIN US65488A1016
Сайт https://nkgenbiotech.com
EBITDA -0.0207
Число акций ао 0.01543 млрд
EV/EBITDA -12.54
Валюта usd
IPO date 2021-07-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +11.9% (0.389)
Change price per week: +8.45% (0.4014)
Change price per month: -43.03% (0.7641)
Change price per 3 month: -67.51% (1.34)
Change price per half year: -66.77% (1.31)
Change price per year: -87.56% (3.5)
Change price per year to date: -86.44% (3.21)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -1.08 0
P/E 0 0
EV/EBITDA -2.21 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -238.56 0
ROE, % 205.33 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.6979 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -81.92 0
Yield Ebitda, % 37.89 5
Yield EPS, % 501.14 10
Total: 5.4
More

Institutions Volume Share, %
RiverNorth Capital Management, LLC 1233095 5.63
Sandia Investment Management LP 471000 2.15
Periscope Capital Inc. 347994 1.59
Karpus Management, Inc. 280525 1.28
Mint Tower Capital Management B.V. 200000 0.91
Alberta Investment Management Corp 200000 0.91
Westchester Capital Management, LLC 105266 0.48
JP Morgan Chase & Company 100557 0.46
Clear Street LLC 73364 0.34
Wells Fargo & Company 47 0

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00073 36.318555985322 1.54048



Head Job title Payment Year of birth
Mr. Sangwoo Park Founder & Executive Director 576k 1970 (54 years)
Dr. Paul Y. Song M.D. CEO & Chairman 650k 1966 (58 years)
Mr. James A. Graf Interim Chief Financial Officer N/A 1965 (59 years)
Ms. Yoonmi Kang SVP of Technical Ops & Development N/A
Dr. Yong Man Kim Ph.D. Chief Scientific Officer 60k 1965 (59 years)
Ms. Denise A. Chua CLS, MBA, MT (ASCP) SVP of Corporate Affairs N/A
Ms. Irene Chang SVP, HR & Corporate Culture N/A
Mr. Ryan Park C.F.A. EVP of Financial Planning & Analysis and Corporate Strategy N/A
Mr. Pierre Gagnon Advisor N/A 1972 (52 years)

Address: United States, Santa Ana. CA, 3001 Daimler Street - open in Google maps, open in Yandex maps
Website: https://nkgenbiotech.com